Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Revance therapeutics s return on capital employed overview - You Need To See This

According to Benzinga Pro data, during Q4, Revance Therapeutics (NASDAQ:RVNC) posted sales of $25.95 million. Earnings were up 15.16%, but Revance Therapeutics still reported an overall loss of $63.10 million. In Q3, Revance Therapeutics brought in $19.75 million in sales but lost $74.38 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.